13F reference period
Q3 2026
Security Snapshot
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 Institutional Ownership
CUSIP: 40637HAF6
13F Institutional Holders and Ownership History from Q3 2023 to Q3 2026
Institutions Reporting
18
Principal
$80.54M
Full value: $80,535,635 · USD principal · 30 Sep 2026Price (% of par)
197.48%
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Debt / NOTE 1.000% 8/1
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F principal
- $80,535,635
- Total 13F market value
- $159,454,276
- Principal change
- -$34,416,595
- Market value change
- -$65,143,183
- Number of holders
- 18
- SEC-reported market price (% of par)
- 197.48%
Latest holder snapshot
3 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- 40637HAF6 - HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1 is tracked under CUSIP 40637HAF6.
- 18 institutions reported positions in Q3 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 52 to 18 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$639.78M
Full value: $639,784,222 · USD · 30 Jun 2026.$159.45M
Full value: $159,454,276 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 18 institutions filings for Q3 2026.
Security key
40637HAF6
13F reference period
Q3 2026
13F holders
18
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 40637HAF6:
As of 30 Sep 2026,
18
institutional investors reported holding
in principal (par value) of
HALOZYME THERAPEUTICS INC - NOTE 1.000% 8/1.
$80.54M
Full value: $80,535,635 · USD · 30 Sep 2026 · Principal (par value)Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Headline period
Q3 2026
Rows shown
1-13 of 13
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | $80,535,635 | $159,454,276 | -$65,143,183 | 197.48% | 18 |
| 2026 Q2 | $439,715,230 | $639,784,222 | -$4,838,429 | 146.22% | 52 |
| 2026 Q1 | $439,034,460 | $564,714,249 | +$8,065,864 | 128.33% | 49 |
| 2025 Q4 | $431,319,360 | $573,383,607 | -$303,578,944 | 132.8% | 55 |
| 2025 Q3 | $655,325,460 | $920,432,391 | +$102,237,538 | 140.75% | 63 |
| 2025 Q2 | $628,830,300 | $718,645,608 | -$27,561,128 | 114.08% | 74 |
| 2025 Q1 | $647,508,446 | $828,761,473 | +$4,645,168 | 128.11% | 77 |
| 2024 Q4 | $672,476,260 | $730,001,496 | -$62,779,579 | 108.09% | 77 |
| 2024 Q3 | $680,559,400 | $810,707,471 | +$105,250,543 | 118.98% | 75 |
| 2024 Q2 | $23,972,237,400 | $717,063,397 | -$3,930,381 | 111.16% | 72 |
| 2024 Q1 | $623,774,400 | $607,993,350 | -$28,940,823 | 97.4% | 70 |
| 2023 Q4 | $658,912,150 | $616,721,993 | -$3,988,874 | 93.09% | 72 |
| 2023 Q3 | $660,082,850 | $622,263,753 | +$620,529,779 | 93.71% | 64 |